NCT06149169 2024-08-21
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Unknown
Clinical Trials
79 trialsNCT06033820 2024-03-13
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
RenJi Hospital
Phase 2 Unknown
NCT06290817 2024-03-04
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05875428 2024-02-08
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT04263584 2024-01-05
COPA-R-CHOP
University Hospital Muenster
Phase 2 Unknown
NCT04089215 2023-11-24
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Unknown
NCT05290090 2023-10-17
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT06074107 2023-10-11
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
BeBetter Med Inc
Phase 2 Unknown
NCT05871684 2023-08-01
A Combination Study of CAR-T Therapy in r/r B-NHL
Ruijin Hospital
Phase 2 Unknown
NCT05887726 2023-07-27
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05940051 2023-07-11
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05940064 2023-07-11
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05816746 2023-05-09
Decitabine and Anti-PD-1 in R/R DLBCL
Chinese PLA General Hospital
Phase 2 Unknown
NCT05823701 2023-04-21
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT05498259 2023-02-03
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05575973 2022-10-12
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
Phase 2 Unknown
NCT03736616 2022-07-22
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
Phase 2 Unknown
NCT05428670 2022-06-23
The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Unknown
NCT05290337 2022-03-22
ZR-CHOP in DLBCL With Specific Gene Abnormality
Fudan University
Phase 2 Unknown
NCT05200312 2022-03-11
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05186558 2022-03-07
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT03837873 2022-01-26
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT03629873 2022-01-03
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04610970 2021-08-18
A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT04827004 2021-04-01
A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT03949062 2021-02-17
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04659434 2020-12-09
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04025593 2020-11-19
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04622579 2020-11-10
R2DLBCL80
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT01965977 2020-10-23
Borma
Samsung Medical Center
Phase 2 Unknown
NCT04544059 2020-09-10
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04425824 2020-06-16
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
ChineseAMS
Phase 2 Unknown
NCT02733380 2020-04-01
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT03600363 2020-03-11
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
Ruijin Hospital
Phase 2 Unknown
NCT04023916 2019-12-11
Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.
ChineseAMS
Phase 2 Unknown
NCT02060656 2019-09-19
LEGEND
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT04021992 2019-08-06
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
Sun Yat-sen University
Phase 2 Unknown
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT01670370 2019-02-15
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT03719989 2018-10-25
EPIC
Seoul National University Hospital
Phase 2 Unknown
NCT03201471 2018-08-02
DLBCL
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03399747 2018-01-16
Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma
Asan Medical Center
Phase 2 Unknown
NCT03383406 2017-12-26
IVAM
Asan Medical Center
Phase 2 Unknown
NCT03373019 2017-12-14
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Fudan University
Phase 2 Unknown
NCT02542111 2017-11-14
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT02753647 2017-11-14
Chidamide Plus R-CHOP in Elderly DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT02955628 2017-02-14
RICE-ibrutinib in Relapsed DLBCL
Singapore General Hospital
Phase 2 Unknown
NCT01653067 2016-10-27
STORM
University Hospital Heidelberg
Phase 2 Unknown
NCT02846584 2016-09-07
a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
Southwest Hospital, China
Phase 2 Unknown